Nursing Study Guide: Transgender Care, Pain Management, and Women's Health

Concepts of Care for Transgender and Nonbinary Patients

Key Terminology and Identity Frameworks

• Core Identity Concepts:

  • Sex Assigned at Birth: The biological label given at birth, primarily determined by external genital anatomy. Terminology includes Assigned Female at Birth (AFAB), Assigned Male at Birth (AMAB), and Intersex. It describes anatomy and biological markers, not gender or sexuality.
  • Gender Identity: A person's innate, deeply felt inner sense of being male, female, nonbinary, genderqueer, or another gender. It answers the internal question, "Who do I know myself to be?" It is not dictated by reproductive anatomy, nor is it a choice or lifestyle.
  • Gender Expression: How an individual presents gender to the outside world through clothing, hairstyles, voice, behavior, mannerisms, and physical appearance. Categories include feminine, masculine, androgynous, gender-conforming, and gender-neutral.
  • Sexual Orientation: Physical, emotional, romantic, or sexual attraction to other people (e.g., heterosexual, gay, lesbian, bisexual, asexual). Sexual orientation is entirely separate and independent from gender identity.

• Deconstructing the LGBTQIA2S+ Acronym:

  • L, G, B, A represent sexual orientation (Lesbian, Gay, Bisexual, Asexual).
  • I represents biological sex variation (Intersex).
  • T, 2S/2+ represent gender identity (Transgender, Two-Spirit).
  • Q represents sexual orientation, gender identity, or both, depending on individual self-identification.
  • Two-Spirit Cultural Distinction: Two-Spirit is a distinct Native American cultural role encompassing spiritual healers, visionaries, and social leaders. It is a traditional Indigenous concept that should not be categorized under Western LGBTQIA2S+ frameworks, nor does it automatically denote transgender or nonbinary identity.

• Specific Terminology (Used strictly as adjectives):

  • Cisgender: An adjective describing an individual whose gender identity aligns with the sex assigned to them at birth.
  • Transgender: An umbrella adjective describing individuals whose gender identity differs from the sex assigned to them at birth. Includes trans women (MtF: assigned male at birth, lives as female) and trans men (FtM: assigned female at birth, lives as male).
  • Nonbinary (Gender Expansive): An adjective describing a gender identity that is not exclusively male or female, falling between, beyond, or outside the binary gender system.
  • Intersex: A biological term describing individuals born with chromosomal patterns, gonads, or genital anatomy that do not fit standard male or female binary definitions.
  • Genderfluid: Describing a gender identity that changes dynamically over time rather than remaining static.
  • Genderqueer: Describing individuals who do not conform to conventional gender roles or expectations. Some nonbinary individuals use this term, while others do not.
  • Gender Nonconforming: Describing identity or expression that expands beyond or resists cultural and social gender expectations.
  • Agender: Describing an individual who identifies as being without a gender.
  • Androgynous: Gender expression that is neither distinctly masculine nor distinctly feminine.

• Congruence versus Gender Dysphoria:

  • Congruence: The state of harmony between one's gender identity and physical body or social presentation.
  • Gender Dysphoria: Clinical emotional or psychological distress resulting from incongruence between assigned sex at birth and gender identity. Being transgender or nonbinary is an identity, whereas gender dysphoria is a state of distress that some, but not all, transgender individuals experience. Mismatch feelings often trace back to early childhood (as early as age $2\text{--}5$  years).

Inclusive Communication and Language Guidelines

• Grammatical Accuracy and Respect:

  • Always use "transgender" and "nonbinary" as adjectives (e.g., "a transgender patient"). Never use them as nouns (e.g., "a transgender") or with past-tense suffixes (e.g., "transgendered").
  • Avoid outdated, clinical, or offensive terms such as "transvestite," "cross-dresser" (when applied to identity), "tranny," "she-male," "he-she," "shim," "trap," or terms implying deception ("masquerading," "fooling," "posing").
  • The term "transsexual" is considered outdated or offensive by many; use it only if a patient explicitly uses it to describe themselves.

• Patient Intake and Pronoun Protocols:

  • Introduce yourself with your name and pronouns to establish a welcoming environment: "Hello, I am [Name], and I will be your nurse today. I use [pronouns]. What name and pronouns would you like me to use?"
  • Move away from the phrase "preferred pronouns." Pronouns are a fundamental component of identity, not a mere preference. Standard sets include she/her/hers, he/him/his, they/them/theirs, and ze/hir/hirs.
  • Do not assume pronouns based on physical appearance, clothing, or voice. An individual wearing a dress may use he/him pronouns; an individual presenting in male attire may ask for she/her pronouns due to workplace non-disclosure.

• EHR Discrepancies and Confidentiality:

  • Official legal identification (driver's licenses, insurance cards) often retains birth names and birth sex due to systemic, legal, or financial barriers. Address the patient by their stated name regardless of medical records.
  • Ask the patient: "How would you prefer that I document your gender in your health record?"
  • Reassure patients that their information is strictly confidential. Gender status, birth name, and medical history must never be disclosed to family, friends, or visitors without explicit written authorization. Legal mandates for disclosure apply only in cases of suspected abuse or immediate harm to self or others.

• Managing Communication Errors:

  • If an incorrect name or pronoun is accidentally used, briefly self-correct and proceed immediately with care: "She—sorry, I mean he—will be back after the x-ray."
  • Avoid prolonged, dramatic apologies ("falling-down apologies"), which shift emotional burden onto the patient and increase discomfort.
  • Advocate for the patient if other healthcare staff or family members misgender them.

Health Equity, Disparities, and Minority Stress

• Health Disparity versus Health Equity:

  • Health Disparity: A higher burden of illness, injury, disability, or mortality experienced by one group relative to another due to systemic barriers.
  • Health Equity: The attainment of the highest level of health for all people, requiring the elimination of avoidable barriers and unfair distribution of resources.
  • Limitations of "Equal Treatment": Treating every patient identically without regard to anatomical or physiological reality produces health inequities. For example, failing to provide prostate screening to a transgender woman or cervical screening to a transgender man based on chart gender markers misses critical preventive care.

• The Minority Stress Model:

  • Distal Stressors: External, objective experiences of prejudice, rejection, or discrimination.
  • Examples: Employment termination due to bias ($25\%$ report job loss; over $75\%$ report workplace discrimination); physical or verbal assault; refusal of healthcare services; microaggressions such as intentional misgendering.
  • Proximal Stressors: Internalized subjective processes occurring as a result of distal stress.
  • Examples: Anticipation of rejection/harassment ($77\%$ of trans employees hide identity or delay transition); delay or avoidance of healthcare ($25\%$ avoid medical care due to fear of mistreatment); internalized transphobia.
  • Pathways to Adverse Health Outcomes: Discrimination and anticipated stigma cause chronic physiological stress activation, leading to depression, PTSD, unhealthy coping mechanisms ($29\%$ monthly illicit drug use, $27\%$ binge drinking), elevated lifetime suicide attempt rates ($40\%$), and systemic inflammation-related chronic diseases.

• Institutional Actions for Inclusion:

  • Display a Patients' Bill of Rights and anti-discrimination policies in prominent public areas.
  • Designate all-gender, single-stall restrooms.
  • Post inclusive imagery (Safe Zone, rainbow symbols).
  • Ensure visitation policies explicitly recognize chosen family.
  • Update electronic health records (EHR) and paper intake forms to collect gender identity, legal name, stated name, pronouns, and organ inventory independently.
  • Guidance Frameworks: Healthy People 2030 (HHS), Institute of Medicine Report (2011), The Joint Commission Field Guide (2011), WPATH Standards of Care (8th ed., 2022), Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health.

Hormone Therapy Protocols and Clinical Considerations

• Prerequisites for Therapy:

  • Informed consent, psychosocial evaluation by a qualified mental health professional, and confirmation that gender incongruence is sustained and marked. Coexisting medical and mental health conditions must be stabilized.
  • Comprehensive discussion of fertility impacts and reproductive preservation prior to initiation.

• Feminizing Hormone Therapy (Male-to-Female / MtF):

  • Regimen: Estrogen (estradiol) combined with an androgen-reducing agent.
  • Expected Changes: Breast tissue development, decreased testicular size, reduced erectile function, decreased libido, reduced sperm count, decreased muscle mass, redistribution of body fat, softening of skin, decreased facial/body hair growth.
  • Estrogen Formulations: Transdermal patches or injectables are preferred over oral estrogen. Oral estrogen undergoes first-pass hepatic metabolism, significantly increasing venous thromboembolism (VTE) risk and altering liver enzymes, C-reactive protein ($CRP$), and binding globulins.
  • Estrogen Risks & Safety Alerts:
  • VTE/Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE), hypertension, hyperglucose, fluid retention, gallbladder disease.
  • Carcinogenesis Nuance: Estrogen does not directly originate cancer; rather, it can feed preexisting hormone-dependent cancers and accelerate their growth rate.
  • Safety Alert: Promptly evaluate unilateral leg pain/swelling, sudden chest pain, or dyspnea.
  • Transdermal Patch Patient Teaching: Apply to clean, dry, hairless skin. Remove the old patch before applying a new one. Wash remaining adhesive off skin. Rotate application sites.
  • Androgen Blockers:
  • Spironolactone: Potassium-sparing diuretic that inhibits testosterone binding. Monitor blood pressure (hypotension risk), serum potassium (hyperkalemia and cardiac dysrhythmias), and renal function ($BUN$/creatinine).
  • Cyproterone Acetate: Synthetic progesterone lowering total endogenous testosterone.
  • 5-Alpha-Reductase Inhibitors (Finasteride, Dutasteride): Block conversion of testosterone to dihydrotestosterone ($DHT$) to treat hair loss and shrink prostate tissue. Side effects include dizziness, cold sweats, and chills.

• Masculinizing Hormone Therapy (Female-to-Male / FtM):

  • Regimen: Testosterone (Depo-Testosterone IM/SubQ, transdermal gels/patches, axillary gel, buccal, or implantable pellets).
  • Expected Changes: Voice deepening, clitoral enlargement, facial/body hair growth (hirsutism), cessation of menses, increased muscle mass, fat redistribution, vaginal dryness, acne, potential male-pattern baldness. Some changes take up to $12\,\text{months}$ to manifest.
  • Testosterone Risks & Safety Alerts:
  • Hepatotoxicity (elevated liver enzymes), dyslipidemia (elevated $LDL$, decreased $HDL$), polycythemia (increased hemoglobin and hematocrit, increasing blood viscosity and clot risk), hyperglucose, elevated uric acid (gout risk), fluid retention/edema.
  • Teaching: Never share injection needles (prevent Hepatitis C and HIV transmission). Wash hands thoroughly and cover application sites after applying topical gels to prevent passive transfer to partners or children.

Surgical Procedures and Perioperative Nursing Care

• Categories and Goals of Gender-Affirming Surgery (GAS):

  • Feminizing (MtF): Mammoplasty (breast augmentation), facial feminization, reduction thyroid chondroplasty (Adam's apple reduction), penectomy, orchiectomy, vaginoplasty.
  • Masculinizing (FtM): Mastectomy with chest contouring, hysterectomy, bilateral salpingo-oophorectomy ($BSO$), vaginectomy, metoidioplasty (creating a small phallus from clitoral tissue), phalloplasty (reconstructing a phallus using radial forearm, thigh, or back tissue flaps with urethral extension).
  • Nullifying (Nonbinary): Procedures creating a body presentation that does not appear distinctly male or female (e.g., genital modification, chest flattening without male contouring, nipple removal).

• Vaginoplasty Perioperative Management:

  • Preoperative: Bowel preparation $24\,\text{hours}$ prior, aggressive hydration, prophylactic IV antibiotics, cessation of tobacco at least $1\,\text{month}$ prior, high-protein nutrition.
  • Postoperative Monitoring:
  • Drains and Catheters: Perineal packing, Jackson-Pratt ($JP$) drain, and indwelling urinary catheter placed. $JP$ drain is removed when output drops below $15\text{--}20\,\text{mL}$ per $24\,\text{hours}$. Urinary catheter remains for approximately $7\,\text{days}$.
  • Pain Management: Perineal ice packs applied for $20\,\text{minutes}$ every hour.
  • Positioning Hazards: Prolonged lithotomy positioning during surgery creates risk for lower extremity compartment syndrome and neurovascular injury. Reassess leg sensation, movement, and calf tenderness.
  • Safety Alert (Vaginal-Rectal Fistula): Stool leaking through the vagina indicates rectal perforation and fistula formation. Requires immediate surgical escalation, temporary colostomy, and wound management.
  • Discharge Protocols (Box 5.6):
  • Require a round-the-clock caregiver for $3\text{--}15\,\text{days}$ post-discharge.
  • Avoid strenuous activity for $6\,\text{weeks}$; no swimming or tub baths for $8\,\text{weeks}$ (showers permitted after first post-op visit).
  • Strict adherence to the individualized vaginal dilation protocol to maintain neovaginal depth and width.
  • Abstain from penetrative intercourse for at least $6\,\text{months}$.

• Chest Binding Safety:

  • Prolonged or overly tight chest binder use causes skin breakdown, soft tissue damage, rib pain, restricted lung expansion, shortness of breath, and postural alterations. Assess binder use and teach safe compression practices.

Lifespan Considerations, Screening, and Care Coordination

• Organ-Based Preventive Screening Rule:

  • Perform clinical screenings based strictly on the anatomical organs and tissues present, regardless of gender marker in the chart.
  • MtF Patients: Require ongoing prostate care (the prostate is not removed during vaginoplasty) and mammography if breast tissue has been augmented.
  • FtM / Nonbinary Patients: Require cervical Pap smears if a cervix is present, ovarian evaluation if ovaries remain, and mammograms/chest exams if residual breast tissue exists.

• Reproductive Options (Discuss Prior to Hormones/Surgery):

  • MtF: Sperm banking prior to initiating hormone therapy or undergoing gonadectomy.
  • FtM: Oocyte (egg) freezing or embryo freezing prior to gonadectomy (for future surrogate implantation).

• Aging and End-of-Life Care:

  • Older transgender adults face elevated fears of discrimination in long-term care facilities, often causing re-concealment of identity or social isolation.
  • Facilitate access for chosen family members. Ensure advance directives specify post-mortem preferences for legal name, stated name, pronouns, and body preparation/clothing (Box 5.2).

Pain Assessment and Multimodal Management

Neurobiology and Physiology of Pain

• Clinical Definition of Pain:

  • Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage. Clinically, pain is whatever the experiencing person says it is, existing whenever they say it does (McCaffery). The patient's self-report is the single most reliable indicator of pain.

• Dual Nature of Pain:

  • Sensory Dimension: Anatomical processing of location, intensity, and duration.
  • Emotional/Cognitive Dimension: Cortical processing producing fear, anxiety, suffering, and behavioral responses.

• Physiological Adaptation in Persistent Pain:

  • Severe pain can exist without elevated blood pressure, tachycardia, diaphoresis, grimacing, or restlessness. In persistent (chronic) pain, the sympathetic nervous system adapts; vital signs typically normalize or drop below baseline. Behavioral signs like sleep or quietly watching television may represent distraction coping rather than comfort.

• The Four Processes of Nociception:

  • Transduction: Noxious mechanical, thermal, or chemical stimuli cause tissue damage, releasing excitatory biochemicals (prostaglandins, bradykinin, histamine, substance P, serotonin). These compounds activate primary afferent nociceptors. Inactivation occurs via nonsteroidal anti-inflammatory drugs ($NSAIDs$), which inhibit cyclooxygenase ($COX$).
  • Transmission: The pain action potential propagates along peripheral nerve fibers to the dorsal horn of the spinal cord, ascending via the spinothalamic tract to the thalamus and cortex.
  • A-Delta Fibers: Lightly myelinated, fast-conducting fibers ($6\text{--}30\,\text{m/s}$). Transmit sharp, localized, rapid pain (reflex withdrawal).
  • C Fibers: Unmyelinated, slow-conducting fibers ($0.5\text{--}2\,\text{m/s}$). Transmit dull, burning, aching, diffuse, continuous pain.
  • Perception: Conscious awareness of pain in the cerebral cortex. Nonpharmacologic cognitive interventions (guided imagery, distraction, virtual reality) act at this level.
  • Modulation: Endogenous descending inhibitory pathways release neurotransmitters (endogenous opioids/endorphins, serotonin, norepinephrine) to suppress pain signals at the spinal cord level. Targeted by opioids, $SNRIs$, and $TCAs$.

Classification and Etiology of Pain

• Acute versus Persistent (Chronic) Pain:

• Nociceptive versus Neuropathic Pain:
  • Nociceptive Pain: Normal processing of noxious stimuli that damages normal tissue or would do so if prolonged. Responds well to nonopioid and opioid analgesics.
  • Somatic Superficial (Cutaneous): Skin and subcutaneous tissue; sharp, throbbing, well-localized (e.g., surgical incision).
  • Somatic Deep: Bone, joint, muscle, connective tissue; dull, aching, localized (e.g., bone metastasis, arthritis).
  • Visceral: Internal organs and lining of body cavities; deep cramping, pressure, diffuse, poorly localized, often referred (e.g., bladder spasms, chest tubes, bowel obstruction).
  • Neuropathic Pain: Abnormal processing of sensory input by the peripheral or central nervous system. Described as burning, shooting, electric shocklike, tingling, "pins and needles," or fiery. Poorly responsive to standard opioids; requires adjuvant analgesics (anticonvulsants, antidepressants).
  • Pain Spatial Patterns:
  • Localized: Confined to the primary origin site.
  • Projected: Diffuse around the origin site.
  • Referred: Perceived at a location distant from the site of origin (e.g., jaw/arm pain during myocardial infarction).
  • Radiating: Travels along a nerve pathway (e.g., sciatica).

Comprehensive Pain Assessment and Clinical Indicators

• Comprehensive Pain History Components (OPQRST):

  • Onset & Duration: When did it begin? Is it constant or intermittent?
  • Provocation & Palliation: What makes it worse or better?
  • Quality: Descriptive terms (sharp, aching, burning, cramping).
  • Region & Radiation: Anatomical location and radiation pattern.
  • Severity / Intensity: Evaluated using a validated scale.
  • Timing & Effect on Function: Impact on sleep, mobility, coughing/deep breathing, $ADLs$, and mood.

• Comfort-Function Goals:

  • Success is not defined by a score of zero. A comfort-function goal is the pain intensity level (e.g., $2\text{--}3/10$) that allows the patient to perform essential functional recovery tasks (coughing, deep breathing, ambulation, physical therapy) with manageable distress.

• Pain Rating Tools:

  • Numeric Rating Scale (NRS): 0–10 scale; standard for verbal adults.
  • Wong-Baker FACES Scale: 6 cartoon faces (0–10); self-report tool for children and adults with mild cognitive impairment. Do not match the patient's facial expression to the scale face.
  • Faces Pain Scale–Revised (FPS-R): Neutral to pained human faces; preferred for older adults.
  • Verbal Descriptor Scale (VDS): Words describing pain degrees (none, mild, moderate, severe).

• Hierarchy of Pain Assessment for Nonverbal Patients:

  1. Attempt self-report using alternative communication (pointing, eye blinks, writing, large-print scales).
  2. Search for potential causes of pain (pathology, surgical procedures, wound care, position changes).
  3. Observe behavioral indicators (grimacing, crying, restlessness, guarding). Use standardized tools: $PACSLAC\text{-}II$ (acute care/dementia) or $PAINAD$ (advanced dementia). Note: A behavioral score reflects distress presence, not numeric intensity.
  4. Obtain proxy reports from family or caregivers.
  5. Perform an empirical trial of analgesics and re-evaluate behavior.

• Opioid Use Disorder (OUD) Considerations:

  • Patients with OUD require evidence-based pain management. Never abruptly discontinue maintenance methadone or buprenorphine. Naltrexone must be stopped prior to opioid therapy. Validate pain reports and manage pain aggressively using multimodal strategies.

Pharmacologic Pain Interventions: Nonopioids, Opioids, and Adjuvants

• Multimodal Analgesia:

  • The administration of two or more classes of analgesics acting through different mechanisms in the peripheral or central nervous systems. Combines nonopioids ($NSAIDs$, acetaminophen), opioids, and adjuvants (gabapentinoids, local anesthetics) to achieve additive or synergistic relief, lower individual drug doses, and reduce adverse effects.

• Preemptive Analgesia:

  • Administering analgesics prior to surgical incision or painful intervention to prevent central sensitization ("wind-up" phenomenon) in the spinal cord, reducing postoperative pain severity and chronic postsurgical pain risk.

• Dosing Strategies:

  • Around-the-Clock (ATC): Scheduled at fixed intervals to maintain stable blood levels for continuous pain ($\ge 12\,\text{hours/day}$).
  • PRN (As Needed): For intermittent pain or prior to painful activities (ambulation, wound care).
  • Breakthrough Pain: Volatile flare-ups of pain occurring despite stable ATC control. Treated with fast-acting rescue doses.

• Nonopioid Analgesics:

  • Acetaminophen (APAP):
  • Mechanism: Central analgesic and antipyretic. No peripheral anti-inflammatory or antiplatelet activity.
  • Safety Limit: Maximum daily dose is $4000\,\text{mg}$ ($4\,\text{g}$) in healthy adults; limit to $3000\,\text{mg}$ ($3\,\text{g}$) or lower in older adults, chronic alcohol users, or hepatic impairment.
  • Toxicity: Overdose causes acute liver necrosis (hepatotoxicity). Check combination products (e.g., Percocet, Vicodin) to prevent accidental cumulative overdose.
  • NSAIDs (Ibuprofen, Naproxen, Celecoxib, Ketorolac, Diclofenac):
  • Mechanism: Block cyclooxygenase ($COX$) enzymes, inhibiting prostaglandin synthesis. Analgesic, antipyretic, and anti-inflammatory.
  • Adverse Effects: Gastrointestinal ulceration and bleeding, renal vasoconstriction (risk of acute kidney injury—ensure adequate hydration), platelet inhibition (increased bleeding), and cardiovascular risk (MI/stroke risk—contraindicated post-CABG surgery).
  • Ketorolac: Short-term use only ($\le 5\,\text{days}$ total across all routes combined) due to high renal and GI toxicity risk.

• Opioid Analgesics:

  • Full Mu Agonists: Morphine, Fentanyl, Hydromorphone, Oxycodone, Hydrocodone, Methadone. No ceiling on analgesia (dose is limited only by adverse effects).
  • Morphine: Hydrophilic; standard baseline opioid. Slow onset, longer duration.
  • Fentanyl: Lipophilic; rapid onset, short duration. Preferred in end-organ renal failure (no active toxic metabolites). Transdermal patch changed every $48\text{--}72\,\text{hours}$ ($12\text{--}18\,\text{hour}$ lag time for initial onset). Safety Alert: Never apply heat (heating pads, fever) over a fentanyl patch; heat accelerates systemic absorption, causing fatal toxicity.
  • Hydromorphone (Dilaudid): Potent agonist ($1.5\,\text{mg}$ IV hydromorphone \n\approx 10\,\text{mg} IV morphine).
  • Methadone: Complex mu agonist and $NMDA$ receptor antagonist. Long, highly variable half-life ($5\text{--}100+\text{hours}$). Risk of accumulation and QT prolongation.
  • Meperidine (Demerol): Avoid routine use. Metabolite normeperidine accumulates in renal impairment or aging, causing neurotoxicity, tremors, and seizures.
  • Key Equianalgesic/Dependence Concepts:
  • Tolerance: Normal physiological adaptation where higher doses are required to maintain analgesia. Tolerance develops to nausea and sedation, but never to constipation.
  • Physical Dependence: Normal physiological state manifested by withdrawal symptoms upon sudden cessation or antagonist administration. Avoided by tapering doses.
  • Addiction: Primary, chronic neurobiological disease characterized by impaired control over drug use, compulsive use, continued use despite harm, and craving.
  • Pseudoaddiction: Iatrogenic syndrome where undertreated pain causes behaviors mimicking addiction (demanding early doses, room-hopping). Resolves when pain is adequately managed.

• Patient-Controlled Analgesia (PCA):

  • Interactive delivery system programmed with a PCA dose, demand/lockout interval (e.g., 6–10 minutes), and optional basal rate.
  • Selection Criteria: Patient must be cognitively intact and physically able to press the button.
  • Basal Rate Warning: Continuous basal infusions in opioid-naïve patients significantly increase respiratory depression and mortality. Avoid basal rates in opioid-naïve individuals.
  • PCA by Proxy: Unauthorized activation of the PCA button by family or staff. Strictly forbidden; only the patient may press the button.

• Adjuvant Analgesics:

  • Gabapentinoids (Gabapentin, Pregabalin): Block CNS voltage-gated calcium channels. First-line for neuropathic pain. Side effects: sedation, dizziness, fall risk. Combined with opioids, FDA warns of severe respiratory depression.
  • Tricyclic Antidepressants (TCAs - Amitriptyline): Block serotonin/norepinephrine reuptake. Effective for neuropathic pain. Anticholinergic side effects, orthostatic hypotension, cardiotoxicity.
  • SNRIs (Duloxetine): Block serotonin/norepinephrine reuptake with fewer anticholinergic effects.
  • Local Anesthetics (Lidocaine, Bupivacaine): Block sodium channels, preventing nerve conduction. Lidocaine $5\%$ patch: 12 hours on, 12 hours off.
  • Local Anesthetic Systemic Toxicity (LAST): Occurs with accidental intravascular injection or absorption. Early signs: perioral numbness, metallic taste, tinnitus, dizziness, confusion. Progresses to seizures, coma, severe bradycardia, dysrhythmias, and cardiovascular collapse.
  • Placebo: Deceitful administration of placebos without informed consent is unethical, illegal, violates the nurse-patient relationship, and is strictly prohibited.

Opioid Safety, Monitoring, and Reversal Protocols

• Pasero Opioid-Induced Sedation Scale (POSS):
  • Sedation consistently precedes opioid-induced respiratory depression and is the most sensitive early indicator.

• Snoring Cue:

  • Snoring indicates upper airway obstruction by the tongue due to deep sedation. It is an ominous sign requiring immediate repositioning, patient arousal, and airway intervention.

• Naloxone (Narcan) Rescue Protocol:

  • Indication: Severe opioid-induced sedation (POSS 4) and respiratory depression (respiratory rate $< 8\text{--}10\,\text{breaths/min}$, shallow depth, hypoxia).
  • Administration: Dilute a $0.4\,\text{mg}$ ampule in $9\,\text{mL}$ normal saline ($0.04\,\text{mg/mL}$). Administer IV slowly ($0.5\text{--}1\,\text{mL}$ every 2 minutes) until the patient is arousable and breathing adequately.
  • Rationale: Pushing naloxone rapidly reverses all analgesia, precipitating severe pain, intense sympathetic surge, hypertension, ventricular dysrhythmias, pulmonary edema, and cardiac arrest.
  • Half-Life Alert: Naloxone's duration of action ($30\text{--}90\,\text{minutes}$) is shorter than that of most opioids. Monitor the patient continuously; repeat naloxone doses may be needed as the first dose wears off.

Nonpharmacologic Interventions and Evaluation

• Physical Modalities:

  • Physical Therapy (PT) and Occupational Therapy (OT) establish functional restoration plans.
  • Cutaneous Stimulation: Cold/ice packs (reduces swelling and inflammation in acute injury or RA; apply 15–20 minutes); Heat packs (increases blood flow, relaxes muscle spasms in OA; never apply heat over transdermal patches or intrathecal pumps); Transcutaneous Electrical Nerve Stimulation (TENS) (sends tingling electrical currents to block spinal pain signals).

• Cognitive-Behavioral Modalities:

  • Distraction, guided imagery, mindfulness, relaxation breathing, music therapy, humor, prayer, aromatherapy.
  • Prerequisite: Requires patient concentration; best applied when pain is mild to moderate or after analgesic administration.

• Reassessment Timelines:

  • Reassess pain intensity, function, sedation, and vital signs at peak drug effect:
  • IV Route: $15\text{--}30\,\text{minutes}$.
  • Oral Route: $45\text{--}60\,\text{minutes}$.
  • Transdermal Route: $12\text{--}24\,\text{hours}$ post-application.

Genetics, Environmental Influences, and Teratogens

Genetics, Inheritance Patterns, and Chromosomal Abnormalities

• Structure of Genetic Material:

  • DNA (Deoxyribonucleic Acid): A double-helix spiral ladder composed of deoxyribose sugar, phosphate groups, and paired nitrogenous bases: Adenine ($A$) pairs strictly with Thymine ($T$); Guanine ($G$) pairs with Cytosine ($C$). Base sequences code for amino acid assembly into functional proteins.
  • Genes: Segments of DNA directing protein production. Somatic cells contain approximately $20,000\text{--}35,000$ genes.
  • Chromosomes: Organized strands of DNA. Human somatic cells contain 46 paired chromosomes (diploid): 22 pairs of autosomes and 1 pair of sex chromosomes ($XX$ female, $XY$ male). Gametes undergo meiosis to contain 23 unpaired chromosomes (haploid).

• Single-Gene Inheritance Patterns:

  • Autosomal Dominant:
  • Expressed when only one copy of a mutated gene is present on an autosome.
  • Affected parent has a $50\%$ ($1\text{ in }2$) chance of passing the trait to each child, regardless of child sex.
  • Examples: Huntington disease, Achondroplasia (dwarfism), Neurofibromatosis, Marfan syndrome, adult polycystic kidney disease.
  • Autosomal Recessive:
  • Requires two copies of the mutated gene (one from each carrier parent) for expression.
  • Carrier parents have a $25\%$ ($1\text{ in }4$) risk of an affected child, $50\%$ risk of a carrier child, and $25\%$ risk of an unaffected non-carrier child per pregnancy.
  • Consanguinity (blood relationship) increases risk.
  • Examples: Tay-Sachs disease (Ashkenazi Jewish descent), Sickle Cell disease (African/Mediterranean descent), Cystic Fibrosis (Northern European descent), Phenylketonuria (PKU).
  • X-Linked Recessive:
  • Mutated gene carried on the X chromosome.
  • Males ($XY$) are primarily affected because they lack a compensating second X chromosome. Females ($XX$) are usually asymptomatic carriers.
  • Affected fathers pass the gene to $100\%$ of daughters (who become carriers) and $0\%$ of sons.
  • Carrier mothers have a $50\%$ chance of passing the disease to sons and a $50\%$ chance of passing carrier status to daughters.
  • Examples: Hemophilia A, Duchenne muscular dystrophy, colorblindness.
  • X-Linked Dominant:
  • Fragile X syndrome (most common inherited intellectual disability in males).

• Chromosomal Abnormalities:

  • Numerical Abnormalities:
  • Trisomy: Presence of an extra single chromosome (47 total). Trisomy 21 (Down syndrome), Trisomy 18 (Edward syndrome), Trisomy 13 (Patau syndrome). Risk increases significantly with advancing maternal age ($\ge 35\,\text{years}$).
  • Monosomy: Missing a single chromosome (45 total). Monosomy X (Turner syndrome, $45,X$) is the only monosomy compatible with postnatal life. Features: female, webbed neck, peripheral edema at birth, short stature, lack of secondary sex traits, cardiac coarctation.
  • Polyploidy: Extra complete sets of chromosomes (69 or 92 total); leads to early spontaneous abortion.
  • Structural Abnormalities: Translocations (attachment of part of a chromosome to another; balanced carriers are healthy, but risk producing unbalanced gametes), deletions, additions, fragile sites.

• Multifactorial Disorders:

  • Caused by an interaction between polygenic susceptibility and environmental factors.
  • Present at birth as single, isolated structural defects (e.g., Neural Tube Defects [spina bifida, anencephaly], cleft lip/palate, pyloric stenosis, congenital heart defects). Secondary defects may occur (e.g., spina bifida causing hydrocephalus due to obstructed spinal fluid flow).

Genetic Counseling, Testing, and Legal Protections

• Principles of Genetic Counseling:

  • Counseling must be strictly nondirective. Counselors provide comprehensive, unbiased information regarding risks, prognosis, and options without recommending specific decisions.
  • Referral Indications: Pregnant woman $\ge 35\,\text{years}$; father $> 40\,\text{years}$; consanguinity; family history of birth defects, intellectual disability, or unexplained stillbirths; multiple miscarriages; exposure to known teratogens; abnormal prenatal screening ($MSAFP$, quad screen, or ultrasound).

• Genetic Information Nondiscrimination Act (GINA of 2008):

  • Federal law prohibiting health insurance companies from adjusting premiums or denying coverage based on genetic predisposition. Prohibits employers from using genetic information in hiring, firing, or promotion decisions.

Teratogens, Environmental Factors, and Fetal Risk Mitigation

• Definition and Principles of Teratogenicity:

  • A teratogen is an environmental agent (infection, drug, chemical, radiation, maternal condition) that causes structural or functional birth defects. Teratogens typically produce multiple anomalies across systems.

• Timing of Exposure (Critical Periods):

  • Pre-Embryonic Period (Weeks 1–2 post-conception): "All-or-none" period. Exposure causes death of the conceptus or undamaged survival.
  • Embryonic Period (Weeks 3–8 post-conception): Period of maximum susceptibility to structural teratogens during organogenesis. Exposure causes major structural malformations.
  • Fetal Period (Weeks 9–40 post-conception): Teratogens cause functional defects or growth restriction. The central nervous system remains vulnerable throughout the entire pregnancy.

• Specific Teratogenic Agents and Preventative Actions:

  • Folic Acid Deficiency: Causes neural tube defects (NTDs) like spina bifida and anencephaly.
  • Dosing: All childbearing-age women: $0.4\text{--}0.8\,\text{mg}$ ($400\text{--}800\,\mu\text{g}$) daily starting at least $1\,\text{month}$ before conception. During pregnancy: $0.6\,\text{mg}$ ($600\,\mu\text{g}$) daily. Women with a prior NTD infant: $4\,\text{mg}$ ($4000\,\mu\text{g}$) daily starting $1\,\text{month}$ prior to conception through the first trimester.
  • Infections: Rubella (causes cataracts, cardiac defects, deafness; administer live vaccine postpartum or $> 4\,\text{weeks}$ before conception), Zika virus (causes microcephaly, eye/hearing defects; avoid travel to endemic areas), Cytomegalovirus ($CMV$), Herpes Simplex ($HSV$), Syphilis, Toxoplasmosis.
  • Drugs/Chemicals: Alcohol (Fetal Alcohol Syndrome; complete abstinence required), Tobacco (maternal vasoconstriction -> IUGR, low birth weight, SIDS), ACE inhibitors, Antiepileptics (valproic acid), Warfarin, Isotretinoin, Lithium, Tetracycline.
  • Maternal Conditions: Hyperthermia (saunas/hot tubs $> 39^\circ\text{C}$ cause NTDs), uncontrolled maternal Diabetes (hyperglycemia is teratogenic), maternal PKU (requires strict low-phenylalanine diet).
  • Mechanical Disruptions: Oligohydramnios ($< 500\,\text{mL}$ amniotic fluid; causes clubfoot compression and pulmonary hypoplasia), Fibrous Amniotic Bands (tears in amnion encircle limbs, causing amputations).

Conception, Embryonic, and Fetal Development

Gametogenesis, Fertilization, and Implantation

• Gametogenesis Comparison:

  • Spermatogenesis: Begins at puberty and continues continuously throughout life. One primary spermatocyte undergoes meiosis to produce 4 functional spermatozoa (2 carrying X, 2 carrying Y). The male gamete determines fetal sex.
  • Oogenesis: Begins during fetal life; all primary oocytes are formed by 30 weeks gestation. One primary oocyte yields 1 mature ovum (carrying an X chromosome) and nonfunctional polar bodies.

• Fertilization and Implantation:

  • Fertilization occurs in the ampulla (outer third) of the fallopian tube within $24\,\text{hours}$ of ovulation. Sperm undergo capacitation to remove protective head coats. Upon entry of one sperm, the zona reaction alters the zona pellucida to block polyspermy. Nuclei fuse, restoring 46 diploid chromosomes (zygote).
  • The zygote undergoes cleavage to form a morula (12–16 cells), entering the uterus at 3–4 days, forming a blastocyst (inner cell mass = embryo/amnion; outer trophoblast = placenta/chorion).
  • Implantation occurs between days 6 and 10 in the upper posterior uterine fundus. Fundal placement ensures a rich blood supply, thick endometrial support preventing deep attachment, and interlacing muscle fibers that compress blood vessels post-delivery to prevent hemorrhage.
  • Trophoblast secretes human chorionic gonadotropin ($hCG$) to maintain the corpus luteum.

Embryonic and Fetal Developmental Timetable

• Developmental Timetable (Fertilization Age):
  • Week 3: Neural plate begins closing into the neural tube. Heart tubes fuse and begin beating at 21–22 days. Primary germ layers form:
  • Ectoderm: Brain, spinal cord, nerves, epidermis, hair, nails, tooth enamel.
  • Mesoderm: Cartilage, bone, skeletal/cardiac muscle, blood vessels, kidneys, gonads.
  • Endoderm: Lining of GI and respiratory tracts, liver, pancreas, bladder.
  • Week 4: Neural tube closes completely. C-shaped curve. Upper/lower limb buds present. 4-chamber heart partitioning begins.
  • Week 6: Heart 4-chamber partitioning complete. Kidneys in pelvis.
  • Week 8: Organogenesis complete. Definite human form. Digits separate. Testes begin differentiating under Y chromosome influence.
  • Week 10: Intestines return from the umbilical cord into the abdominal cavity.
  • Week 12: Fetal heart tones audible by Doppler ($110\text{--}160\,\text{bpm}$). External genitalia visually distinguishable. Kidneys secrete urine into amniotic fluid.
  • Week 16: Quickening felt by multiparous women. Eyes face forward.
  • Week 20: Quickening felt by primiparous women. Vernix caseosa and lanugo cover skin. Brown fat deposits complete.
  • Week 24: Surfactant production begins in primitive alveoli. Lower limit of viability.
  • Week 28: Alveoli mature. Eyelids reopen. Bone marrow takes over hematopoiesis.
  • Weeks 38–40: Full term.

Placental, Cord, Amniotic, and Circulatory Systems

• Placental Structure and Function:

  • Maternal Side: Decidua basalis, rough, divided into cotyledons. Fetal Side: Chorion and amnion, smooth, shiny.
  • Functions: Metabolic synthesis; gas/nutrient transfer via simple diffusion ($O_2$, $CO_2$), facilitated diffusion (glucose), active transport (amino acids, calcium, iron), and pinocytosis (maternal $IgG$ passive immunity); endocrine production ($hCG$, Estrogen, Progesterone, $hCS/hPL$).
  • Anatomical Variations: Battledore (marginal cord insertion), Succenturiate lobe, Velamentous insertion (vessels branch across membranes; risk of rupture and vasa previa hemorrhage).

• Umbilical Cord (AVA):

  • Contains Two Umbilical Arteries (carry deoxygenated blood and metabolic waste away from fetus to placenta) and One Umbilical Vein (carries oxygenated, nutrient-rich blood from placenta to fetus). Encased in protective Wharton's jelly.

• Amniotic Fluid:

  • Volume is $500\text{--}1000\,\text{mL}$ at term. Derived from fetal urine and fluid transport.
  • Oligohydramnios ($< 500\,\text{mL}$): Caused by renal agenesis or placental insufficiency; leads to clubfoot deformation and pulmonary hypoplasia.
  • Polyhydramnios / Hydramnios ($> 2000\,\text{mL}$): Caused by anencephaly or esophageal atresia preventing fetal swallowing.

• Fetal Circulation and the Three Shunts:

$\text{Placenta} \rightarrow \text{Umbilical Vein} \rightarrow \mathbf{Ductus\ Venosus}\ \text{(bypasses liver)} \rightarrow \text{IVC} \rightarrow \text{Right Atrium} \rightarrow \mathbf{Foramen\ Ovale}\ \text{(bypasses lungs)} \rightarrow \text{Left Atrium} \rightarrow \text{Aorta}$$\text{Deoxygenated return} \rightarrow \text{Right Ventricle} \rightarrow \text{Pulmonary Artery} \rightarrow \mathbf{Ductus\ Arteriosus}\ \text{(bypasses lungs)} \rightarrow \text{Descending Aorta} \rightarrow \text{Umbilical Arteries}$

• Postnatal Adaptations: First breath expands lungs, dropping pulmonary resistance. Left atrial pressure rises above right atrial pressure, closing the Foramen Ovale. Cord clamping closes the Ductus Venosus. Elevated arterial $PO_2$ constricts the Ductus Arteriosus. All three shunts convert into fibrous ligaments.

  • Twinning:

• Monozygotic (Identical): 1 ovum + 1 sperm split. Same sex, identical genes. Division timing determines membranes: $< 3\,\text{days}$ (2 amnions/2 chorions); $4\text{--}8\,\text{days}$ (2 amnions/1 chorion [diamniotic/monochorionic]); $8\text{--}12\,\text{days}$ (1 amnion/1 chorion [monoamniotic/monochorionic - high cord tangle risk]); $> 13\,\text{days}$ (conjoined).

• Dizygotic (Fraternal): 2 ova + 2 sperm. Always 2 amnions and 2 chorions.

Maternal Adaptations, Antepartum Care, and Diagnostic Indicators

Diagnostic Signs of Pregnancy

• Presumptive Indications (Subjective—experienced by patient):

  • Amenorrhea, nausea and vomiting ($60\text{--}80\%$), fatigue, urinary frequency, breast tenderness and enlargement, quickening (16–20 weeks).

• Probable Indications (Objective—documented by examiner):

  • Chadwick's Sign: Bluish-purple discoloration of cervix, vagina, and labia due to hyperemia.
  • Goodell's Sign: Softening of the cervix (feels like lips/earlobe).
  • Hegar's Sign: Softening of the lower uterine segment (isthmus).
  • Ballottement, Braxton Hicks contractions, abdominal enlargement, palpable fetal outline, uterine souffle (blow matching maternal pulse), positive $hCG$ test.

• Positive Indications (Diagnostic—caused ONLY by a fetus):

  • Auscultated fetal heart sounds (Doppler at 9–12 weeks; fetoscope at 16–20 weeks; rate $110\text{--}160\,\text{bpm}$).
  • Fetal movements felt by an experienced examiner.
  • Visualization of embryo/fetus on ultrasound.

Systemic Maternal Adaptations and Relief Measures

• Reproductive & Cardiovascular Adaptations:

  • Uterus grows from $70\,\text{g}$ ($10\,\text{mL}$ capacity) to $1100\text{--}1200\,\text{g}$ ($5000\,\text{mL}$ capacity).
  • Blood volume expands $45\%$. Plasma volume increases $40\text{--}60\%$, while RBC mass increases $20\text{--}30\%$, causing Physiologic Anemia of Pregnancy (hemodilution).
  • True Anemia Thresholds: Hemoglobin $< 11\,\text{g/dL}$ (1st and 3rd trimesters) or $< 10.5\,\text{g/dL}$ (2nd trimester); Hematocrit $< 33\%$ (1st/3rd) or $< 32\%$ (2nd).
  • Cardiac output increases $50\%$. Hypercoagulable state (fibrinogen increases $50\%$).
  • Supine Hypotensive Syndrome: Supine position causes heavy uterus to compress the inferior vena cava and aorta, dropping cardiac output and blood pressure (faintness, lightheadedness, nausea, decreased placental perfusion). Intervention: Left lateral recumbent position or hip wedge.

• GI, GU, Integumentary, and Musculoskeletal Adaptations:

  • Progesterone relaxes lower esophageal sphincter (heartburn/pyrosis) and slows intestinal motility (constipation/hemorrhoids). Relief: Small frequent meals, sit upright post-meals, high fluid/fiber intake.
  • $GFR$ increases $50\%$, spilling glucose into urine (glycosuria) and increasing UTI/pyelonephritis risk.
  • Melasma (mask of pregnancy), Linea nigra, Striae gravidarum.
  • Progressive lordosis causes backache (Relief: pelvic tilt exercises). Pubic symphysis loosens (waddling gait). Sharp right-sided round ligament pain (Relief: bend toward pain, heat).

Gestational Age Estimation and Clinical Metrics

• Nägele's Rule:

$\text{EDD} = \text{First Day of Last Normal Menstrual Period (LNMP)} - 3\,\text{Months} + 7\,\text{Days} + 1\,\text{Year}$

• Example: LNMP October 30, 2022 $\rightarrow$ Subtract 3 months (July 30) $\rightarrow$ Add 7 days and 1 year = August 6, 2023.

  • Fundal Height Progression:

• 12 Weeks: Palpable above symphysis pubis.

• 16 Weeks: Midway between symphysis pubis and umbilicus.

• 20 Weeks: At the umbilicus ($\approx 20\,\text{cm}$).

• 16 to 36 Weeks: Height in centimeters equals gestational age in weeks ($\pm 2\,\text{cm}$).

• 36 Weeks: Reaches xiphoid process (maximum height; causes dyspnea).

• 40 Weeks: Drops due to fetal descent into pelvis (lightening).

  • GTPAL System:

• G (Gravida): Total number of pregnancies, including current one.

• T (Term): Pregnancies delivered at $\ge 37$ (or 38) weeks.

• P (Preterm): Pregnancies delivered between 20 and 36 (or 37) weeks.

• A (Abortions): Pregnancies ending before 20 weeks (spontaneous or elective).

• L (Living): Total currently living children. (Twins count as 1 pregnancy/GTP event, but are counted individually under Living).

Women's Health Across the Lifespan

Health Maintenance and Preventive Screening

• Preventive Screening Protocols:
  • Breast Self-Awareness: Women should be familiar with normal breast appearance and feel, reporting new lumps, dimpling, skin changes, or nipple retraction promptly.
  • Mammography: Annual or biennial screening starting at age 40–50; biennial for ages 50–74. Schedule after menses to minimize discomfort.
  • Pap Test: Begins at age 21 to detect abnormal cervical cells at the squamocolumnar junction. HPV co-testing.
  • Fecal Occult Blood Test (FOBT): Annual colon cancer screening $\ge 50$. Avoid NSAIDs/aspirin for 7 days; avoid red meat and vitamin C for 72 hours prior.

Breast Disorders: Benign and Malignant

• Benign Breast Disorders:

  • Fibrocystic Changes: Nodular, tender, fluid-filled bilateral cysts fluctuating with menses in reproductive-age women. Treatment: Reduce caffeine, supportive bra, NSAIDs.
  • Fibroadenoma: Firm, rubbery, mobile, non-tender solitary mass common in teens/20s.
  • Ductal Ectasia: Perimenopausal; dilated subareolar ducts filled with debris, irregular mass, nipple retraction, thick discharge. Requires biopsy to rule out malignancy.
  • Intraductal Papilloma: Menopausal; small papillary growth in duct causing serosanguineous nipple discharge. Excise.

• Malignant Breast Tumors:

  • Infiltrating ductal carcinoma ($70\text{--}80\%$) is most common. Lymphatic invasion produces peau d'orange (orange-peel dimpling) appearance. Most common site: upper outer quadrant.
  • Risk Factors: Age $> 55$, Caucasian race, early menarche ($< 12$), late menopause ($> 55$), nulliparity/first birth $> 30$, BRCA1/BRCA2 mutations, chest radiation, postmenopausal HRT, obesity, alcohol consumption.
  • Therapies: Lumpectomy, modified radical mastectomy, sentinel node biopsy (reduces lymphedema risk), radiation, chemotherapy, Tamoxifen (for ER-positive tumors), Trastuzumab/Herceptin (for HER2-positive tumors).

Menstrual, Gynecologic, and Pelvic Floor Disorders

• Menstrual & Gynecologic Conditions:

  • Primary Amenorrhea: No menses by age 15 with normal secondary sex traits, or age 13 without traits. (Cause: Turner syndrome, anatomical defects). Secondary Amenorrhea: Absence of menses for 3+ months in previously regular women. (Rule out pregnancy first!).
  • Primary Dysmenorrhea: Menstrual pain without pelvic pathology, caused by excessive endometrial prostaglandin E2 inducing severe uterine contractions and ischemia. Treatment: NSAIDs taken at flow onset; oral contraceptives.
  • Endometriosis: Growth of endometrial tissue outside the uterus. Triad: cyclic deep pelvic pain, dyspareunia (painful intercourse), dyschezia (painful defecation), plus infertility. Treatment: OCPs, progestins, GnRH agonists (Lupron), surgical ablation.
  • Premenstrual Syndrome (PMS) / PMDD: Luteal phase physical/emotional symptoms with 7 symptom-free follicular days. PMDD features severe anger/depression. Treatment: SSRIs (fluoxetine), exercise, reduced caffeine/sugar/salt.
  • Elective Termination: Medical abortion ($\le 7\text{--}9\,\text{weeks}$: Mifepristone then Misoprostol); Surgical (vacuum aspiration $\le 12\,\text{weeks}$; D&E in 2nd trimester). Post-care: report temperature $> 37.8^\circ\text{C}$ ($100^\circ\text{F}$), no tampons/intercourse/douching for 1 week.

• Pelvic Floor Dysfunction:

  • Cystocele: Anterior vaginal wall prolapse of bladder $\rightarrow$ stress incontinence, incomplete emptying.
  • Rectocele: Posterior wall prolapse of rectum $\rightarrow$ difficulty defecating, bowel pressure.
  • Enterocele: Upper posterior prolapse/herniation of pouch of Douglas.
  • Uterine Prolapse: Downward sagging of uterus into vagina.
  • Kegel Exercises: Contract pubococcygeus muscle for 3–10 seconds, relax 10 seconds; 30–80 repetitions daily to strengthen pelvic floor. Do not perform while urinating.

Menopause, Osteoporosis, and Cardiovascular Health in Women

• Menopause and Hormonal Management:

  • Confirmed after 12 consecutive months of amenorrhea. Average age 45–50.
  • Estrogen decline causes genitourinary atrophy (atrophic vaginitis, dyspareunia), vasomotor instability (hot flashes), LDL elevation/HDL reduction, and accelerated bone loss.
  • Menopause Hormone Therapy (MHT):
  • Estrogen-Only (ERT): Reserved ONLY for women who have had a hysterectomy.
  • Estrogen + Progesterone (HRT): Essential for women with an intact uterus (progesterone prevents estrogen-induced endometrial hyperplasia and cancer).

• Osteoporosis Prevention and Treatment:

  • Bone mineral density T-score $\le -2.5$ on DEXA scan. Results in loss of height, dorsal kyphosis (dowager's hump), and fracture risk.
  • Interventions: Calcium ($1200\,\text{mg/day}$), Vitamin D ($600\text{--}800\,\text{IU/day}$), weight-bearing exercise. Bisphosphonates (Alendronate): Take first thing in the morning with a full glass of water, 30 minutes before food, and remain sitting/standing upright for 30 minutes.

• Cardiovascular Disease in Women:

  • Leading cause of death in women. Myocardial infarction symptoms are frequently atypical: sudden severe fatigue, weakness, dyspnea, nausea, upper abdominal pain, indigestion, back/jaw pain, rather than classic crushing chest pain.

Infectious Disorders and Sexually Transmitted Infections

• Gynecologic & Sexually Transmitted Infections:
  • Candidiasis (Yeast): Curd-like white discharge, severe itching. Treat with azole creams or oral fluconazole.
  • Bacterial Vaginosis (BV): Thin gray-white discharge, fishy odor, clue cells. Treat with metronidazole.
  • Trichomoniasis: Frothy yellow-green discharge, strawberry cervix. Treat with single $2\,\text{g}$ oral dose of metronidazole or tinidazole. Strictly avoid alcohol for 24–72 hours post-treatment. Treat partner.
  • Chlamydia & Gonorrhea: Asymptomatic carriers; cause Pelvic Inflammatory Disease (PID), tubal scarring, ectopic pregnancy, and infertility. Treat with Ceftriaxone IM plus Azithromycin/Doxycycline.
  • Pelvic Inflammatory Disease (PID): Ascending upper tract infection; cervical motion tenderness, fever, severe pelvic pain.
  • Toxic Shock Syndrome (TSS): Toxin-producing Staphylococcus aureus linked to high-absorbency tampons ($> 4\,\text{hours}$) or barrier contraceptives. Symptoms: high fever ($> 38.9^\circ\text{C}$ / $102^\circ\text{F}$), severe hypotension, sunburn-like rash with desquamation of palms/soles.